Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Etiome logo — Preemptive medicine for better health

Etiome

Preemptive medicine for better health

Founded 2021 United States Cambridge, United States 23 employees

General Information

Company Name Etiome
Founded Year 2021
Location United States Cambridge, United States +1
Employees 23
Social

Get notified when Etiome moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Etiome

Etiome, founded in 2021 by Flagship Pioneering, is leveraging the potential of preemptive medicine to advance health outcomes. With the slogan "Preemptive medicine for better health," Etiome focuses on creating groundbreaking therapies tailored to specific disease stages.

The company's proprietary platform, Temporal Biodynamics™, harnesses expansive population data, single cell omics, and machine learning. This innovative approach enables Etiome to accurately capture the complexity of disease progression and develop targeted Biostaged Medicines that aim to stop or reverse diseases efficiently.

Without a specific headquarters or disclosed last investment round, Etiome is still an intriguing prospect for investors who are enthusiastic about the future of personalized medicine. The company's cutting-edge approach and foundation by a reputable organization position it as a forward-thinking player in the healthcare industry.

Taxonomy: Preemptive Medicine, Biostaged Medicines, Temporal Biodynamics, Disease Progression Modeling, Targeted Therapies, Disease Stage Characterization, Machine Learning in Medicine, Single Cell Omics, Population Data Analysis, AI in Drug Discovery, Precision Medicine, Biotechnology Innovation, Health Data Analytics, Therapeutics Development, Disease Intervention

Services & Products

Development of Biostaged Medicines
Disease Prevention Strategies
Deployment of Stage-specific Therapies

Target Customers

Patients at Risk of Debilitating Diseases Healthcare Providers Medical Researchers

No funding data available for Etiome yet.

Get notified when Etiome raises funding

Etiome Alternatives & Competitors

Etiome vs
Ennen Oy
Ennen Oy

A health tech startup developing a web app for early detection of memory diseases.

Etiome vs
Neuron23
Neuron23 United States

Combining cutting-edge science, human genetics, and a patient-centered approach to transform how we...

Series D
28 employees
Etiome vs
Octave
Octave United States

Your partner in precision care for multiple sclerosis (MS) and beyond.

Grant
88 employees
Biotechnology, Health Care

FAQ About Etiome

Preemptive medicine for better health
Etiome was founded in 2021.
Etiome is headquartered in Cambridge, United States.
Etiome has approximately 23 employees.
Etiome offers: Development of Biostaged Medicines, Disease Prevention Strategies, Deployment of Stage-specific Therapies.
Top alternatives and competitors to Etiome include Ennen Oy, Neuron23, Octave, Walden Biosciences, Arkuda Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Etiome and Ennen Oy are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Etiome and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy